Precision CNS-specific biomarker measurement for Alzheimer’s disease

Plasma phosphorylated tau at threonine 217 (pTau 217) is currently the most effective blood biomarker for Alzheimer’s disease, demonstrating strong concordance with amyloid-β (Aβ) and tau PET imaging and the largest fold difference between amyloidnegative and amyloid-positive individuals.

This application note evaluates the performance of the SPEAR UltraDetect™ BD-pTau 217 Assay, designed to target CNS-specific pTau 217 species, in a memory clinic cohort and in a cohort of young healthy individuals.